Company
Gilead Sciences
Gilead Sciences has 61 drugs tracked on RxWires: 10 post-market, 2 approved, 16 in Phase 3, 3 in Phase 2/3, 19 in Phase 2, 1 in Phase 1/2, 9 in Phase 1.
- Ticker
- GILD
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| liposomal amphotericin B (AmBisome®) | Post-Market | Fungal Infection |
| Tenofovir | Post-Market | Non-Hodgkin's Lymphoma, Burkitt's |
| F/TAF (High Dose Tablet) | Post-Market | HIV-1-infection |
| BIC/LEN FDC | Post-Market | HIV-1 Infection |
| Ranolazine | Post-Market | Hypertrophic Cardiomyopathy |
| Tenofovir DF | Post-Market | Hepatitis B |
| FTC/TAF | Post-Market | Hiv |
| Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC) | Post-Market | Hepatitis C, Chronic |
| Biktarvy 50Mg-200Mg-25Mg Tablet | Post-Market | Harm Reduction |
| Genvoya Oral dose | Post-Market | Healthy Volunteers |
| GENVOYA | Approved | |
| COMPLERA | Approved | |
| LDV/SOF | Phase 3 | Hepatitis C Virus Infection |
| SOF/VEL | Phase 3 | Hepatitis C Virus Infection |
| Bictegravir/Lenacapavir (BIC/LEN) FDC | Phase 3 | HIV-1-infection |
| Sacituzumab govitecan-hziy (SG) | Phase 3 | Triple Negative Breast Cancer |
| Seladelpar | Phase 3 | Primary Biliary Cholangitis |
| AZLI 75 mg two times a day (BID)/ three times a day (TID) | Phase 3 | Cystic Fibrosis |
| Capecitabine | Phase 3 | HER2-negative Breast Cancer |
| ambrisentan | Phase 3 | Pulmonary Arterial Hypertension |
| Genvoya | Phase 3 | HIV Risk |
| Zimberelimab | Phase 3 | Non-small Cell Lung Cancer |
| RTV | Phase 3 | HIV-1 Infection |
| E/C/F/TAF | Phase 3 | HIV |
| AZLI | Phase 3 | Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization |
| CLEVUDINE + TENOFOVIR PLACEBO | Phase 3 | HBe Negative Chronic Hepatitis B |
| Bulevirtide | Phase 3 | Chronic Hepatitis Delta |
| Sacituzumab govitecan | Phase 3 | Triple Negative Breast Cancer |
| Bictegravir | Phase 2/3 | HIV-1-infection |
| GS-3242 Tablet | Phase 2/3 | HIV-1-infection |
| Oral Lenacapavir | Phase 2/3 | HIV-1-infection |
| Andecaliximab | Phase 2 | Rheumatoid Arthritis |
| B/F/TAF | Phase 2 | HIV-1 Infection |
| GS-5885 | Phase 2 | Hepatitis C, Chronic |
| FTC/RPV/TDF | Phase 2 | HIV-1 Infection |
| GS-1179 | Phase 2 | HSV-2 Infection |
| Cilofexor Dose B | Phase 2 | Primary Biliary Cholangitis |
| GS-5718 | Phase 2 | Rheumatoid Arthritis |
| Selgantolimod | Phase 2 | Chronic Hepatitis B |
| GS-9450 | Phase 2 | HCV Infection |
| Domvanalimab | Phase 2 | Head and Neck Squamous Cell Carcinoma |
| tenofovir disoproxil fumarate | Phase 2 | HIV |
| Obeldesivir | Phase 2 | RSV Infection |
| Lanraplenib | Phase 2 | Sjogren's Syndrome |
| Idelalisib | Phase 2 | Amyloidosis |
| Dapivirine | Phase 2 | HIV-1-infection |
| GS-9674 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| Tilpisertib | Phase 2 | Ulcerative Colitis |
| Denikitug | Phase 2 | HER2-negative |
| TAF | Phase 2 | Chronic Hepatitis B |
| TUB-040 | Phase 1/2 | Ovarian Cancer |
| GS-2426 | Phase 1 | Advanced Solid Tumors |
| GS-9411 | Phase 1 | Cystic Fibrosis |
| GS-1206 | Phase 1 | Solid Tumor |
| GS-5319 | Phase 1 | Advanced Solid Tumor |
| CAL-101 | Phase 1 | Chronic Lymphocytic Leukemia (CLL) |
| Selonsertib | Phase 1 | Diabetic Kidney Disease |
| Alpelisib | Phase 1 | Breast Cancer |
| GS-0201 | Phase 1 | Advanced Solid Tumors |
| KITE-439 | Phase 1 | Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer |
| Stribild | Not Applicable | HIV |
Latest
- GENVOYA: patent 8981103 expired 2026-10-26
- GENVOYA: patent 7635704 expired 2026-10-26
- gilead sciences filed 8-K
- gilead sciences filed 8-K
- gilead sciences filed 8-K
Follow Gilead Sciences on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.